Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

@article{Robert2011IpilimumabPD,
  title={Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.},
  author={Caroline Robert and Luc Thomas and Igor E Bondarenko and Steven J. O'Day and Jeffrey Weber and Claus Garbe and C{\'e}l{\`e}ste Lebb{\'e} and J Baurain and Alessandro Testori and Jean Jacques Grob and Neville Davidson and Jon M. Richards and Michele Maio and A. H. W. Hauschild and Wilson H. Miller and Pedro Gasc{\'o}n and Michal Lotem and Kaan Harmankaya and Ramy Ibrahim and Stephen Francis and T Chen and Rachel Humphrey and Axel Hoos and Jedd D Wolchok},
  journal={The New England journal of medicine},
  year={2011},
  volume={364 26},
  pages={2517-26}
}
BACKGROUND Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma. METHODS We randomly assigned 502 patients with previously untreated metastatic melanoma, in a 1:1 ratio, to ipilimumab (10 mg per… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS